Akeso's Ivonescimab Outperforms Pembrolizumab in Phase III Lung Cancer Study

Key Facts

In a development that signals a potential shift in oncology treatment standards, Akeso has announced positive Phase III results for its drug Ivonescimab. According to the HARMONi-2 study, the drug demonstrated a statistically significant overall survival benefit compared to pembrolizumab. The trial focused on patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), marking a major clinical milestone for Akeso and its partner, Summit Therapeutics Inc.

The clinical evidence suggests that Ivonescimab monotherapy is more effective than the current market leader for this specific patient population. Per market data, Akeso's stock (9926.HK) stood at 85.65 HKD at close September 1, 2026. During that session, the instrument reached a daily high of 90.3 HKD and a low of 85.2 HKD, reflecting investor reaction to the clinical advancements and the competitive positioning of the drug.

Traders should watch the 85.2 HKD level as a potential support point based on the price action at close September 1, 2026. While the HARMONi-2 study was conducted in China, its success against a major global competitor provides a strong foundation for future growth. With no major upcoming economic catalysts scheduled in the immediate calendar, market attention is expected to remain on the long-term commercial implications of these Phase III results.